

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number
WO 2004/010938 A2

(51) International Patent Classification⁷:

A61K

(74) Agent: CLARK, Paul, T.; Clark & Elbing LLP, 101 Federal Street, Boston, MA 02110 (US).

(21) International Application Number:

PCT/US2003/023456

(22) International Filing Date: 29 July 2003 (29.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/399,538 30 July 2002 (30.07.2002) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US 60/399,538 (CON)
Filed on 30 July 2002 (30.07.2002)

(71) Applicant (for all designated States except US): SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. [FR/FR]; 51-53 rue du Docteur Blanche, F-75016 Paris (FR).

(72) Inventor; and

(75) Inventor/Applicant (for US only): SCHROFF, Robert, W. [US/US]; 7306 164th Place, S.W., Edmonds, WA 98026 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/010938 A2

(54) Title: USE OF CHYMASE INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF ARTERIO-VENOUS GRAFT FAILURE

(57) Abstract: Disclosed is a method of treating A-V graft failure in a subject in need of such treatment, said method comprising administering to said subject an effective amount of an agent that inhibits the production, release or neo-intima generating effects of chymase, wherein said effective amount of said agent is an amount effective to treat said A-V graft failure.

USE OF CHYMASE INHIBITORS FOR THE PREVENTION AND/OR
5 TREATMENT OF ARTERIO-VENOUS GRAFT FAILURE

Background of the Invention

Approximately 100,000 arterio-venous (A-V) vascular access procedures are performed each year in the US to provide access for the performance of renal dialysis (Stanley *et al.*, *J. Vasc. Surg.* 1996, 23, 172-181). The most common material used for prosthetic dialysis access is polytetrafluoroethylene (PTFE or Gore-Tex), but approximately 60% of these grafts fail each year, usually due to stenosis at the venous end (Culp *et al.*, *Am. J. Kidney Dis.* 1995, 26, 341-346; Churchill *et al.*, *J. Am. Soc. Nephrol.* 1994, 4, 1809-1813; and Feldman *et al.*, *Kidney Int.* 1993, 43, 1091-1096). Similar lesions develop in PTFE grafts placed into the arterial circulation, and again there is a tendency for the distal end of the graft to be more effected, but the rate of stenosis is not as great as in A-V grafts (Cantelmo *et al.*, *J. Cardiovasc. Surg. (Torino)* 1989, 30, 910-915). Studies have shown that stenosis in A-V grafts is associated with the proliferation and build-up of smooth muscle cells (Kohler *et al.*, *J. Vasc. Surg.* 1999, 30, 744-751 and Rekhter *et al.*, *Arterioscler. Thromb.* 1993, 13, 609-617).

Percutaneous transluminal coronary angioplasty (PTCA) is an established therapy for obstructive coronary artery diseases. PTCA may be accomplished by balloon dilation, or more recently by the use of intracoronary stents. The long-term efficacy of PTCA has been limited by the occurrence of restenosis (Lin *et al.*, *Circulation* 1989, 79, 1374-1387). Restenosis following PTCA, like the stenosis that occurs following A-V graft placement, is characterized by the proliferation and migration of smooth muscle cells and the subsequent development of a neointima (Lin *et al.*, *supra*). Angiotensin II has been shown to play a role in neointimal development (Dzau *et al.*,

Hypertension. 1991, 18(suppl II), II-100-II-105). The involvement of angiotensin II in the pathophysiology of restenosis following PTCA was subsequently confirmed by the demonstration that both angiotensin converting enzyme (ACE) inhibitors and angiotensin II antagonists inhibit neointima development following balloon angioplasty (Powell *et al.*, *Science* 1989, 245, 186-188 and Osterrieder *et al.*, *Hypertension* 1991, 18 (suppl II), II-60-II-64). Based on these observations, ACE inhibitors were used in clinical trials to prevent restenosis following PTCA, but were found to be ineffective (MERCATOR Study Group, *Circulation* 1992, 86, 100-110 and Faxon, *J. Am. Coll. Cardiol.* 1995, 25, 362-369).

The failure of ACE inhibitors in clinical trials, in contrast to their efficacy in animal models, lead to investigations into the source of this discrepancy. The source of the discrepancy seemed to be related to species differences in angiotensin II formation in humans versus rats and other species commonly used in animal models of restenosis. While ACE plays an important role in the production of angiotensin II from angiotensin I in rat vascular tissue, the primary route for generation of angiotensin II in humans, monkey and dog vascular tissue is chymase (Okunishi *et al.*, *J. Hypertens.* 1984, 2, 277-284; Okunishi *et al.*, *Biochem. Biophys. Res. Commun.* 1987, 149, 1186-1192; Okunishi *et al.*, *Jpn. J. Pharmacol.* 1993, 62, 207-210; Shiota *et al.*, *FEBS Lett.* 1993, 323, 239-242; and Takai *et al.*, *FEBS Lett.* 1997, 421, 86-90). Chymase from these species cleaves angiotensin I to produce angiotensin II, while chymase from rats degrades angiotensin I to inactive fragments (Le Trong *et al.*, *Proc. Natl. Acad. Sci. USA* 1987, 84, 364-3679). Balloon injury of dog carotid arteries results in significant activation of vascular tissue chymase levels, but not ACE levels (Shiota *et al.*, *supra*). While an ACE inhibitor has little inhibitory effect on the development of neointima following balloon injury in the dog carotid, significant inhibition of neointima development has been reported with the use of an angiotensin II receptor antagonist (Okunishi *et al.*, *J. Hypertens.* 1994, 12(suppl 3), S132).

Chymase is produced primarily in connective tissue mast cells, and secreted into the interstitium. Some anti-allergenic drugs are capable of stabilizing mast cells, and thus inhibiting the release of chymase by mast cells. Tranilast, (N-(3,4-dimethoxycinnamoyl) anthranilic acid; available from A.G. 5 Scientific, San Diego, CA) is an anti-allergy drug that stabilizes mast cells and mast cell degranulation (Okunishi *et al.*, *Jpn. J. Pharmacol.* 1993, 62, 207-210 and Shiota *et al.*, *supra*). Tranilast suppresses neointima formation in balloon-injured dog coronary arteries by suppression of vascular chymase levels (Okunishi *et al.*, *Jpn. J. Pharmacol.* 1993, 62, 207-210; Shiota *et al.*, *supra*, 10 Takai *et al.*, *supra*; and Le Trong *et al.*, *supra*). Tranilast was subsequently shown upon oral administration over three months in clinical trials to markedly reduce the rate of restenosis following PTCA (Takai *et al.*, *supra*).

In contrast to Tranilast, which inhibits chymase release by mast cells, NK3201, (2-(5-formylamino-6-oxo-3-phenyl-1,6,-dihydropyrimidine-1-yl)-N-15 {2,3-dioxo-6-(2-pyridyloxy)-1-phenylmethyl}hexyl acetamide) is a direct inhibitor of chymase activity (Takai *et al.*, *Circulation* 2001, abstract number 1135; and United States Patent No. 6,271,238). Similar to Tranilast, NK3201 has been shown to inhibit intimal hyperplasia in the dog carotid artery balloon injury model (Takai *et al.*, *Circulation* 2001, abstract number 1135). In 20 addition, NK3201 has demonstrated the ability to inhibit vascular proliferation and subsequent neointima formation in a dog model of vein graft injury (Takai *et al.*, *Life Sci.* 2001, 69, 1725-1732). This model consists of bypass grafting of the carotid artery with a piece of the ipsilateral jugular vein. When the vein tissue is placed into the artery environment, the result is proliferation and 25 neointima formation similar to that observed in the carotid artery balloon injury model.

Summary of the Invention

The present invention relates to the use of agents that inhibit the production, release or neo-intima generating effects of chymase for treating and/or inhibiting A-V graft failure. Accordingly, in a first aspect, the invention

5 features a method of treating A-V graft failure in a subject, preferably a human, in need of such treatment that includes administering an effective amount of an agent that inhibits the production, release, or neo-intima generating effects of chymase to the subject, where the effective amount of the agent is that amount effective in treating the A-V graft failure. In one embodiment, the graft failure

10 includes intimal hyperplasia, which can include the proliferation and migration of smooth muscle cells, such as can occur at the venous end of an A-V graft. Therefore, in another aspect, the invention features a method of treating intimal hyperplasia associated with an A-V graft by administering an agent that inhibits the production, release, or neo-intima generating effects of chymase.

15 An example of an agent useful for any of the foregoing methods of the invention is N-(3,4-dimethoxycinnamoyl)anthranilic acid, or a pharmaceutically acceptable salt thereof. Other agents useful for any of the foregoing methods of the invention include angiotensin II receptor antagonists or chymase inhibitors, such as 2-(5-formylamino-6-oxo-3-phenyl-1,6,-

20 dihydropyrimidine-1-yl)-N-{2,3-dioxo-6-(2-pyridyloxy)-1-phenylmethyl} hexyl acetamide.

Detailed Description

A-V graft failure displays intimal hyperplasia at the venous end of the

25 graft that is similar in composition to that observed in animal models of arterial balloon injury and bypass grafting of a vein into an artery. Thus, compounds that show efficacy in these latter models would be useful in treating and/or inhibiting A-V graft failure. Importantly, although chymotrypsin type proteases have been considered to participate in some fashion in diseases such

as asthma, allergy, inflammations, rheumatism, hypertension, heart failure, myocardial infarction, cardiac hypertrophy, vascular injuries accompanied by angiogenesis and atheroma, nephritis and renal insufficiency, the use of known inhibitors of neointimal development in PTCA restenosis models or vein graft 5 stenosis models, e.g., chymase inhibitors, in the treatment and/or inhibition of A-V graft failure has not been previously suggested.

Chymase inhibitors are well known to those of skill in the art. A non-exclusive list of suitable chymase inhibitors would comprise, without limitation, the compounds described in the following references: U.S. Patent 10 Nos.: 6,410,576; 6,372,744; 6,355,460; 6,271,238; 6,159,938; 6,080,738; 5,948,785; 5,814,631; 5,723,316; 5,691,335; 5,367,064; 5,266,465; 5,079,336; 5,723,316; and 6,271,238. Also well known are assays for determining chymase inhibitory activity (see, e.g., U.S. Patent Nos.: 6,410,576; 6,372,744; 6,355,460; 6,271,238; 5,723,316; 6,080,738; 5,948,785; 5,814,631; 5,723,316; 15 and 5,691,335).

Preferred compounds for use in methods according to the invention would include, without limitation, angiotensin II receptor antagonists, mast cell stabilizing agents, and chymase inhibitors. Particularly preferred compounds for use in methods according to the invention would include TRANILAST and 20 NK-3201, and pharmaceutically acceptable salts thereof. The synthesis of NK-3201 is detailed in US Patent No. 6,271,238 (see synthesis example No. 55 therein).

Compounds for use in methods according to the invention can be formulated and administered to a subject using the guidance provided herein 25 along with techniques well known in the art. The preferred route of administration ensures that an effective amount of compound reaches the target. Guidelines for pharmaceutical administration in general are provided in, for example, *Remington: The Science and Practice of Pharmacy 20th Edition*, Ed. Gennaro, Lippincott, Williams & Wilkins Publishing, 2000, which is 30 hereby incorporated by reference herein.

Pharmaceutical compositions for use in the method of the invention may be formulated such that the pharmaceutically active compound is used alone or mixed with excipients or carriers and administered orally or parenterally such as by an injection, inhalant, tablets, granules, subtle granules, powder, capsules, 5 suppositories, instillations, paste agents, ointments, sprays etc. As excipients or carriers, pharmaceutically acceptable additives are selected and the type and composition are determined according to the administration route and administration method. For example, in the case of an injection, sodium chloride or saccharides such as glucose, mannitol etc. is generally preferable.

10 In the case of oral preparations, starch, lactose, crystalline cellulose, magnesium stearate etc. are preferable.

The content of the pharmaceutically active compound in a pharmaceutical composition varies depending on the preparation, but is usually in the range of 0.1% to 100% by weight, preferably 1% to 98% by weight. For 15 example, in the case of an injection, the active ingredient is contained in the range of usually 0.1% to 30% by weight, preferably 1% to 10% by weight. In the case of an oral preparation, the pharmaceutically active compound is used with additives in the form of tablets, capsules, powder, granules, liquid, dry syrup etc. The capsules, tablets, granules and powder contain generally 5% to 20 100% by weight of the pharmaceutically active compound, preferably 25% to 98% by weight.

In general, an effective dosage of active ingredient may be varied. However, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained. The selected dosage depends upon the 25 desired therapeutic effect, on the route of administration, and on the duration of the treatment, all of which are within the realm of knowledge of one of ordinary skill in the art. Generally, dosage levels of between 0.0001 mg/kg to 100 mg/kg of body weight daily are administered to humans or other animals, e.g., mammals. A preferred dosage range is 0.01 mg/kg to 100.0 mg/kg of

body weight daily, more preferably 1.0 mg/kg to 10.0 mg/kg of body weight daily, which can be administered as a single dose or divided into multiple doses, or provided for continuous administration.

Further, an effective dosage of active ingredient may be administered in 5 a sustained release composition such as those described in the following patents: U.S. Patent No. 5,672,659 teaches sustained release compositions comprising a bioactive agent and a polyester; U.S. Patent No. 5,595,760 teaches sustained release compositions comprising a bioactive agent in a gelable form; U.S. Application No. 08/929,363, filed September 9, 1997, 10 teaches polymeric sustained release compositions comprising a bioactive agent and chitosan; U.S. Application No. 08/740,778, filed November 1, 1996, teaches sustained release compositions comprising a bioactive agent and cyclodextrin; and U.S. Application No. 09/015,394, filed January 29, 1998, teaches absorbable sustained release compositions of a bioactive agent. The 15 teachings of the foregoing patents and applications are incorporated herein by reference.

Other features and advantages of the present invention will be apparent from the present description and also from the claims. It is believed that one skilled in the art can, based on the description herein, utilize the present 20 invention to its fullest extent. The following specific embodiments are therefore to be construed as merely illustrative and not limitative of the remainder of the disclosure in any way whatsoever. All of the documents cited herein are hereby incorporated by reference in their entirety.

From the above description, one skilled in the art can easily ascertain the 25 essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various uses and conditions. Thus, other embodiments are also within the claims.

What is claimed is:

Claims

1. A method of treating A-V graft failure in a subject in need of such treatment, said method comprising administering an effective amount of an agent that inhibits the production, release, or neo-intima generating effects of chymase to said subject, wherein said effective amount of said agent is an amount effective to treat said A-V graft failure.
2. A method according to claim 1 wherein said A-V graft failure comprises intimal hyperplasia.
3. A method of treating intimal hyperplasia associated with an A-V graft, said method comprising administering an agent that inhibits the production, release or neo-intima generating effects of chymase.
4. A method according to any one of claims 1-3, wherein said agent is N-(3,4-dimethoxycinnamoyl)anthranilic acid, or a pharmaceutically acceptable salt thereof.
5. A method according to any one of claims 1-3, wherein said agent is an angiotensin II receptor antagonist.
6. A method according to any one of claims 1-3, wherein said agent is a chymase inhibitor.
7. A method according to claim 6, wherein said chymase inhibitor is 2-(5-formylamino-6-oxo-3-phenyl-1,6-dihdropyrimidine-1-yl)-N-{2,3-dioxo-6-(2-pyridyloxy)-1-phenylmethyl}hexyl acetamide, or a pharmaceutically acceptable salt thereof.
8. A method according to any one of claims 1 – 7, wherein said subject is human.

9. A method according to any one of claims 1 – 8, wherein said treatment comprises inhibition of intimal hyperplasia.
10. A method according to claim 9, wherein said intimal hyperplasia comprises the proliferation and migration of smooth muscle cells.
11. A method according to claim 9, wherein said intimal hyperplasia occurs at the venous end of said A-V graft.
12. A method according to any one of claims 8 – 11, wherein said chymase inhibitor is 2-(5-formylamino-6-oxo-3-phenyl-1,6,-dihydropyrimidine-1-yl)-N-{2,3-dioxo-6-(2-pyridyloxy)-1-phenylmethyl}hexyl acetamide, or a pharmaceutically acceptable salt thereof.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number
WO 2004/010938 A3

(51) International Patent Classification⁷: **A61K 31/505** (74) Agent: CLARK, Paul, T.; Clark & Elbing LLP, 101 Federal Street, Boston, MA 02110 (US).

(21) International Application Number:
PCT/US2003/023456

(22) International Filing Date: 29 July 2003 (29.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/399,538 30 July 2002 (30.07.2002) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/399,538 (CON)
Filed on 30 July 2002 (30.07.2002)

(71) Applicant (for all designated States except US): SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. [FR/FR]; 51-53 rue du Docteur Blanche, F-75016 Paris (FR).

(72) Inventor; and

(75) Inventor/Applicant (for US only): SCHROFF, Robert, W. [US/US]; 7306 164th Place, S.W., Edmonds, WA 98026 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
24 June 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/010938 A3

(54) Title: USE OF CHYMASE INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF ARTERIO-VENOUS GRAFT FAILURE

(57) Abstract: Disclosed is a method of treating A-V graft failure in a subject in need of such treatment, said method comprising administering to said subject an effective amount of an agent that inhibits the production, release or neo-intima generating effects of chymase, wherein said effective amount of said agent is an amount effective to treat said A-V graft failure.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/23456

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/505
US CL : 514/274

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/274

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6,271,238 B1 (SUZUKI et al.) 07 August 2001 (07.08.01), see the entire document.	1-7

Further documents are listed in the continuation of Box C.

See patent family annex.

- * Special categories of cited documents:
 - "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 - "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 - "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
 - "&" document member of the same patent family
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

Date of the actual completion of the international search

31 December 2003 (31.12.2003)

Date of mailing of the international search report

23 APR 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized officer

Raymond J. Henley III

Telephone No. 703-308-1135

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/23456

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claim Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claim Nos.: 8-12 because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.